Back

Glutamate Dehydrogenase as a Superior Biomarker for Choledocholithiasis Risk Stratification

2026-02-17 gastroenterology Title + abstract only
View on medRxiv
Show abstract

Background and AimsCholedocholithiasis (CDL) is a common condition that can lead to serious complications, requiring effective risk stratification for timely intervention. While current guidelines use clinical predictors, imaging, and laboratory markers for risk assessment, the role of glutamate dehydrogenase (GLDH) in CDL remains poorly understood. This study aims to evaluate its potential as a clinical biomarker for identifying patients with CDL. MethodsThis single-center cohort study identif...

Predicted journal destinations